FLT3 inhibitors – an ideal strategy for treating FLT3-mutated AML
Combining CLL drugs to overcome the problem of resistance
Current research on CD19 targeted CAR T-cells in relapsed B-cell ALL
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Where will leukemia research go next?